RU2768019C2 - Клетка - Google Patents

Клетка Download PDF

Info

Publication number
RU2768019C2
RU2768019C2 RU2017121892A RU2017121892A RU2768019C2 RU 2768019 C2 RU2768019 C2 RU 2768019C2 RU 2017121892 A RU2017121892 A RU 2017121892A RU 2017121892 A RU2017121892 A RU 2017121892A RU 2768019 C2 RU2768019 C2 RU 2768019C2
Authority
RU
Russia
Prior art keywords
car
nucleic acid
ser
acid sequence
gly
Prior art date
Application number
RU2017121892A
Other languages
English (en)
Russian (ru)
Other versions
RU2017121892A3 (OSRAM
RU2017121892A (ru
Inventor
Мартен ПЮЛЕ
Шон КОРДОБА
Симоби ОНУОХА
Саймон ТОМАС
Original Assignee
Отолус Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2768019(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Отолус Лимитед filed Critical Отолус Лимитед
Publication of RU2017121892A publication Critical patent/RU2017121892A/ru
Publication of RU2017121892A3 publication Critical patent/RU2017121892A3/ru
Application granted granted Critical
Publication of RU2768019C2 publication Critical patent/RU2768019C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
RU2017121892A 2014-12-24 2015-12-23 Клетка RU2768019C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1423172.4 2014-12-24
GB201423172 2014-12-24
PCT/GB2015/054137 WO2016102965A1 (en) 2014-12-24 2015-12-23 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022102250A Division RU2022102250A (ru) 2014-12-24 2015-12-23 Клетка

Publications (3)

Publication Number Publication Date
RU2017121892A RU2017121892A (ru) 2019-01-24
RU2017121892A3 RU2017121892A3 (OSRAM) 2019-05-28
RU2768019C2 true RU2768019C2 (ru) 2022-03-23

Family

ID=55066668

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2022102250A RU2022102250A (ru) 2014-12-24 2015-12-23 Клетка
RU2017121892A RU2768019C2 (ru) 2014-12-24 2015-12-23 Клетка

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2022102250A RU2022102250A (ru) 2014-12-24 2015-12-23 Клетка

Country Status (26)

Country Link
US (8) US11091532B2 (OSRAM)
EP (3) EP3237442B1 (OSRAM)
JP (5) JP6633081B2 (OSRAM)
KR (6) KR20200003939A (OSRAM)
CN (2) CN114107212A (OSRAM)
AU (5) AU2015370679C1 (OSRAM)
BR (1) BR112017013690A2 (OSRAM)
CA (2) CA3224507A1 (OSRAM)
CL (3) CL2017001314A1 (OSRAM)
DK (2) DK3237442T3 (OSRAM)
ES (2) ES2744910T3 (OSRAM)
FI (1) FI3560953T3 (OSRAM)
HR (1) HRP20240357T1 (OSRAM)
HU (2) HUE046262T2 (OSRAM)
IL (4) IL292508B2 (OSRAM)
LT (1) LT3560953T (OSRAM)
MX (1) MX2017006233A (OSRAM)
PL (2) PL3560953T3 (OSRAM)
PT (2) PT3237442T (OSRAM)
RS (1) RS65343B1 (OSRAM)
RU (2) RU2022102250A (OSRAM)
SG (2) SG11201704084VA (OSRAM)
SI (1) SI3560953T1 (OSRAM)
SM (1) SMT202400134T1 (OSRAM)
WO (1) WO2016102965A1 (OSRAM)
ZA (1) ZA201703381B (OSRAM)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
CN114107212A (zh) 2014-12-24 2022-03-01 奥托路斯有限公司 细胞
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
US20180044404A1 (en) 2015-03-05 2018-02-15 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
CN108610420B (zh) * 2016-12-13 2023-09-26 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
AU2017384900B2 (en) * 2016-12-28 2020-12-10 GC Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
WO2018132427A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
AU2018236461B2 (en) 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN110520524A (zh) * 2017-04-14 2019-11-29 综合医院公司 靶向肿瘤微环境的嵌合抗原受体t细胞
ES2905377T3 (es) * 2017-04-18 2022-04-08 Autolus Ltd Célula
JP2020517259A (ja) * 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN110650975B (zh) * 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
CN109385402A (zh) * 2017-08-11 2019-02-26 上海恒润达生生物科技有限公司 一种等比例混合两种靶点cart细胞的制备方法及应用
CN107446937B (zh) * 2017-09-05 2020-12-25 深圳华云生物技术有限公司 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
MX2020002901A (es) 2017-09-19 2020-07-22 Massachusetts Inst Technology Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
EP4279584A3 (en) * 2017-10-16 2024-03-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN108101994B (zh) * 2018-01-04 2020-09-15 广东万海细胞生物科技有限公司 抗cd19抗体及其应用
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
WO2019157533A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
CN110157738B (zh) * 2018-02-13 2023-06-27 亘喜生物科技（上海）有限公司 靶向cd19和cd22的工程化免疫细胞及其应用
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN112119096B (zh) 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
SG11202012339WA (en) * 2018-07-13 2021-01-28 Nanjing Legend Biotech Co Ltd Co-receptor systems for treating infectious diseases
HUE069503T2 (hu) 2018-09-27 2025-03-28 Autolus Ltd Kiméra antigénreceptor
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
GB201820547D0 (en) * 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
KR20220010722A (ko) * 2019-05-16 2022-01-26 난징 레전드 바이오테크 씨오., 엘티디. Cd4 결합 모이어티를 포함하는 면역 세포 수용체
EP3980453A4 (en) * 2019-06-07 2023-07-05 The Trustees of the University of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021009510A1 (en) 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
CA3147020A1 (en) 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
CN112390891B (zh) * 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
CN110903401A (zh) * 2019-11-20 2020-03-24 浙江大学 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
AR120563A1 (es) * 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quimérico cd19 y cd22 y sus usos
JP7744914B2 (ja) * 2020-02-04 2025-09-26 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート ハプテン標識細胞によりキメラ抗原受容体ｔ細胞を刺激する方法およびそのための組成物
US20230139885A1 (en) * 2020-03-11 2023-05-04 Fundació Institut De Recerca Contra La Leucèmia Josep Carreras Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all)
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
US11981932B2 (en) 2020-06-17 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
WO2022020800A2 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
TW202216754A (zh) * 2020-08-25 2022-05-01 美商賽特免疫治療公司 雙特異性抗體car細胞免疫療法
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
CN112481284B (zh) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
KR102393776B1 (ko) 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2023016554A1 (zh) * 2021-08-13 2023-02-16 上海医药集团股份有限公司 靶向cd22的抗原结合蛋白及其用途
KR102829757B1 (ko) * 2021-11-17 2025-07-09 (주)이노베이션바이오 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
WO2024137508A1 (en) * 2022-12-19 2024-06-27 Development Center For Biotechnology Chimeric antigen receptors, nucleic acids encod ing the same, and uses thereof in treating cancers
AU2024240255A1 (en) * 2023-03-17 2025-10-02 Cartesian Therapeutics, Inc. Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors
WO2024246526A1 (en) 2023-05-30 2024-12-05 Autolus Limited Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2024250037A1 (en) * 2023-06-02 2024-12-05 Northeastern University Targeted immune cell therapy utilizing trail and tnf mediated apoptosis
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055668A1 (en) * 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014065961A1 (en) * 2012-10-24 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
WO2014124143A1 (en) * 2013-02-06 2014-08-14 Anthrogenesis Corporation Modified t lymphocytes having improved specificity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299011A1 (fr) 1975-01-29 1976-08-27 Obert Jean Claude Generateur d'aerosols de part
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
EP1629012B1 (en) * 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
ES2532124T3 (es) 2005-12-16 2015-03-24 Amgen Research (Munich) Gmbh Medios y procedimientos para el tratamiento de enfermedades tumorales
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9868774B2 (en) 2011-10-20 2018-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014138704A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
IL311390A (en) 2013-03-15 2024-05-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
SI3546572T1 (sl) 2013-05-13 2024-06-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
EP3021853A1 (en) 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
DK3071222T3 (da) 2013-11-21 2020-11-16 Ucl Business Ltd Celle
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
CN114107212A (zh) 2014-12-24 2022-03-01 奥托路斯有限公司 细胞
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201610515D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Cell
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN112119096B (zh) 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055668A1 (en) * 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014065961A1 (en) * 2012-10-24 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
WO2014124143A1 (en) * 2013-02-06 2014-08-14 Anthrogenesis Corporation Modified t lymphocytes having improved specificity

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ABKEN H. et al., Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells, Frontiers in immunology, 2013, V. 4, Article 371. *
BRIDGEMAN J. S. et al., The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex, The Journal of Immunology, 2010, V. 184, N. 12, С. 6938-6949. *
BURNS W. R. et al., A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas, Cancer research, 2010, V. 70, N. 8, p.3027-3033. *
CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, V. 65, N. 10, p.1357-1369. *
COLMAN P. M., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994, V. 145, N. 1, p.33-36. *
CORDOBA S. P. et al., The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor, Blood, The Journal of the American Society of Hematology, 2013, V. 121, N. 21, p.4295-4302. *
de FELIPE P., Polycistronic Viral Vectors, Current gene therapy, 2002, V. 2, N. 3, p.355-378. *
DOLEZAL O. et al., ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers, Protein engineering, 2000, V. 13, N. 8, p.565-574. *
JENA B. et al., Driving CAR-based T-cell therapy to success, Current hematologic malignancy reports, 2014, V. 9, N. 1, p.50-56. *
KIPRIYANOV S. M. et al., Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity, Protein engineering, 1997, V. 10, N. 4, p. 445-453. *
MAEDA Y. et al., Engineering of functional chimeric protein G-VargulaLuciferase, Analytical biochemistry, 1997, V. 249, N. 2, p.147-152. *
MAUS M. V. et al., T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer immunology research, 2013, V. 1, N. 1, p.26-31. *
PAKULA A.A. et al., Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p.289-310. *
PAKULA A.A. et al., Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p.289-310. KIPRIYANOV S. M. et al., Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity, Protein engineering, 1997, V. 10, N. 4, p. 445-453. ЛИКАРЬ Ю. Н. et al., Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, p.23-31. MAUS M. V. et al., T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer immunology research, 2013, V. 1, N. 1, p.26-31. BURNS W. R. et al., A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas, Cancer research, 2010, V. 70, N. 8, p.3027-3033. TEPLYAKOV A. et al., Antibody modeli *
RIEUX-LAUCAT F. et al., Inherited and somatic CD3 ζ mutations in a patient with T-cell deficiency, New England Journal of Medicine, 2006, V. 354, N. 18, p.1913-1921. *
SAFDARI Y. et al., Antibody humanization methods-a review and update, Biotechnology and Genetic Engineering Reviews, 2013, V. 29, N. 2, p.175-186. *
TEPLYAKOV A. et al., Antibody modeling assessment II. Structures and models, Proteins: Structure, Function, and Bioinformatics, 2014, V. 82, N. 8, p.1563-1582. *
YOKOSE N. et al., CD20-positive T cell leukemia/lymphoma: case report and review of the literature, Annals of hematology, 2001, V. 80, N. 6, p.372-375. *
ЛИКАРЬ Ю. Н. et al., Использование мутированного варианта человеческой деоксицитидинкиназы в качестве репортерного гена для оценки адоптивной Т-клеточной терапии, Вопросы гематологии, онкологии и иммунопатологии в педиатрии, 2012, V. 11, N. 2, p.23-31. *
РОЙТ А. и др., Иммунология. Пер. с английского, Москва, Мир, 2000. *

Also Published As

Publication number Publication date
CA3224507A1 (en) 2016-06-30
KR20220129684A (ko) 2022-09-23
AU2015370679A1 (en) 2017-06-01
EP4368704A3 (en) 2024-05-29
US10174099B2 (en) 2019-01-08
KR102376242B1 (ko) 2022-03-21
IL301458A (en) 2023-05-01
FI3560953T3 (fi) 2024-03-21
JP6633081B2 (ja) 2020-01-22
IL292508A (en) 2022-06-01
SMT202400134T1 (it) 2024-05-14
PL3560953T3 (pl) 2024-05-13
RU2017121892A3 (OSRAM) 2019-05-28
US20170340705A1 (en) 2017-11-30
PT3237442T (pt) 2019-09-26
AU2015370679C1 (en) 2020-09-10
DK3237442T3 (da) 2019-09-23
AU2024278248A1 (en) 2025-01-30
ZA201703381B (en) 2018-08-29
LT3560953T (lt) 2024-05-10
HUE046262T2 (hu) 2020-02-28
DK3560953T5 (da) 2024-09-02
RU2022102250A (ru) 2022-03-23
EP3560953B1 (en) 2024-01-31
AU2020213352B2 (en) 2022-08-18
AU2015370679B2 (en) 2020-05-21
JP2018501794A (ja) 2018-01-25
AU2022205170B2 (en) 2025-02-27
IL274903A (en) 2020-07-30
IL274903B (en) 2022-07-01
CL2018003216A1 (es) 2019-02-01
IL252208B (en) 2021-10-31
IL252208A0 (en) 2017-07-31
US20170340704A1 (en) 2017-11-30
JP2021036913A (ja) 2021-03-11
AU2022205170A1 (en) 2022-09-15
CL2018003217A1 (es) 2019-02-01
KR20230152824A (ko) 2023-11-03
KR102376244B1 (ko) 2022-03-21
EP4368704A2 (en) 2024-05-15
NZ731778A (en) 2024-02-23
MX2017006233A (es) 2017-10-24
CN107002045A (zh) 2017-08-01
KR20200003939A (ko) 2020-01-10
PL3237442T3 (pl) 2020-02-28
US20200181232A1 (en) 2020-06-11
DK3560953T3 (da) 2024-04-02
US12398194B2 (en) 2025-08-26
CL2017001314A1 (es) 2017-12-15
JP2024055976A (ja) 2024-04-19
AU2022205169A1 (en) 2022-09-15
SG11201704084VA (en) 2017-06-29
US20180371054A1 (en) 2018-12-27
HRP20240357T1 (hr) 2024-06-07
US20170369550A1 (en) 2017-12-28
AU2020213352A1 (en) 2020-08-27
ES2744910T3 (es) 2020-02-26
JP6909844B2 (ja) 2021-07-28
CA2970440A1 (en) 2016-06-30
KR20210098557A (ko) 2021-08-10
US20230331810A1 (en) 2023-10-19
ES2976197T3 (es) 2024-07-26
IL292508B1 (en) 2023-04-01
BR112017013690A2 (pt) 2018-03-06
SG10202111107RA (en) 2021-11-29
SI3560953T1 (sl) 2024-05-31
US11091532B2 (en) 2021-08-17
US20190161531A1 (en) 2019-05-30
RS65343B1 (sr) 2024-04-30
EP3560953A1 (en) 2019-10-30
KR102085349B1 (ko) 2020-03-06
WO2016102965A1 (en) 2016-06-30
KR20170092695A (ko) 2017-08-11
CN107002045B (zh) 2025-10-21
JP7514746B2 (ja) 2024-07-11
US10981970B2 (en) 2021-04-20
US20250353893A1 (en) 2025-11-20
RU2017121892A (ru) 2019-01-24
JP2020022508A (ja) 2020-02-13
EP3237442B1 (en) 2019-07-10
US10098926B2 (en) 2018-10-16
AU2022205169B2 (en) 2024-09-26
CN114107212A (zh) 2022-03-01
IL292508B2 (en) 2023-08-01
HUE066020T2 (hu) 2024-07-28
JP2022002546A (ja) 2022-01-11
US11034750B2 (en) 2021-06-15
KR20210098556A (ko) 2021-08-10
EP3237442A1 (en) 2017-11-01
PT3560953T (pt) 2024-03-26

Similar Documents

Publication Publication Date Title
AU2022205170B2 (en) Chimeric Antigen Receptor
AU2019348975B2 (en) Chimeric antigen receptor
CA2941159A1 (en) Chimeric antigen receptor
RU2810092C2 (ru) Химерный антигенный рецептор
HK1243425B (en) Cell
HK1243425A1 (en) Cell

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant
HZ9A Changing address for correspondence with an applicant